HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategy

Presenters: Andreas Raue, PhD, Project Leader, Senior Director, Head of Drug Intelligent Science (DIS®) at HiFiBiO Therapeutics and Robert Petit, PhD, Senior Scientific Advisor

HFB301001 is being developed as a potential novel treatment option for cancer coupled with a patient stratification biomarker in solid tumor indications.

More information about these and other programs in the HiFiBiO Therapeutics pipeline is available at


About HiFiBiO Therapeutics

HiFiBiO Therapeutics is transforming the field of immunotherapy by combining proprietary single-cell profiling technologies with advanced data intelligence and deep knowledge of immune system biology. This approach enables the development of novel antibody therapies that are paired with biomarkers to predict patient response. HiFiBiO Therapeutics is working actively to address unmet medical needs around the world through its own innovative pipeline programs and open-innovation partnerships with world-renowned industry and academic researchers. The company’s strong global footprint features cutting-edge laboratories on three continents, in Cambridge, Mass., Paris, Shanghai and Hong Kong. To learn more, please visit

HiFiBiO® and DIS® are trademarks of HiFiBiO and its affiliates.